All Stories

  1. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  2. Shared genetic and molecular architecture between insulin resistance and cognitive performance
  3. Educational Attainment Polygenic Scores and School Performance in Adolescents With Psychiatric Disorders: A Population-Based Analysis of 86,122 Individuals From the iPSYCH2015 Case-Cohort
  4. Personality domains in early stages of psychosis: a systematic review and meta-analysis
  5. Schizophrenia Genetics Modulates Clinical Depressive Features
  6. Polygenic predisposition to transdiagnostic symptom dimensions and treatment outcomes across psychiatric disorders
  7. The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts
  8. Psychiatric Risk Governance Across Jurisdictions: A Comparative Analysis of Involuntary Treatment, Community Treatment Orders, and Forensic Mental Health Services
  9. Asenapine for aggressive behaviours in psychiatric disorders: a systematic review of efficacy and real-world effectiveness
  10. Factors associated with drug–drug interactions involving citalopram in the UK Biobank
  11. Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
  12. Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data
  13. Correction: Mild motor signs and depression: more than just medication side effects?
  14. Mild motor signs and depression: more than just medication side effects?
  15. Local patterns of genetic sharing between neuropsychiatric and insulin resistance-related conditions
  16. Specific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex
  17. Oropharyngeal microbiota in patients with psychotic disorders: A scoping review on compositional and functional alterations
  18. Predictive coding in neuropsychiatric disorders: A systematic transdiagnostic review
  19. The interface of depression and diabetes: treatment considerations
  20. Shared genetics and causal relationship between sociability and the brain’s default mode network
  21. Polygenic scores and antidepressant treatment outcomes in major depression: a critical integrative review
  22. The gut microbiota's role in bulimia nervosa and binge eating disorder: etiological insights and therapeutic implications from a scoping review
  23. Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder
  24. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
  25. Anhedonia is associated with a specific depression profile and poor antidepressant response
  26. Molecular landscape of the overlap between Alzheimer’s disease and somatic insulin-related diseases
  27. Unravelling the joint genetic architecture between psychiatic and insulin-related traits in the general population
  28. The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity
  29. Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?
  30. The clinical perspective on late-onset depression in European real-world treatment settings
  31. Mirtazapine blood levels and antidepressant response
  32. Shared familial risk for type 2 diabetes mellitus and psychiatric disorders: a nationwide multigenerational genetics study
  33. Shared genetics linking sociability with the brain's default mode network.
  34. The association of glucose metabolism measures and diabetes status with Alzheimer’s disease biomarkers of amyloid and tau: A systematic review and meta-analysis
  35. Local patterns of genetic sharing challenge the boundaries between neuropsychiatric and insulin resistance-related conditions
  36. Pharmacological treatments for psychotic depression: a systematic review and network meta-analysis
  37. The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?
  38. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  39. Genetic relationship between the immune system and autism
  40. Genetic relationship between the immune system and autism spectrum disorder and traits
  41. 33. SHARED GENETICS LINKING SOCIABILITY WITH THE BRAIN'S DEFAULT MODE NETWORK
  42. T13. EPIGENETIC FACTORS INFLUENCING CO-MORBIDITY OF INSULIN-RELATED SOMATIC AND BRAIN DISORDERS
  43. W12. LOOKING BEYOND LABELS: DEFINING DIMENSIONAL PSYCHIATRIC SYMPTOM CLUSTERS WITH INSULIN-RELATED SOMATIC MEASURES BASED ON LARGE POPULATION-BASED GENETIC DATASETS
  44. W16. THE MULTIVARIATE GENETIC ARCHITECTURE OF PSYCHIATRIC AND SOMATIC INSULIN RESISTANCE-RELATED MULTIMORBIDITY
  45. Correlation between emotion dysregulation and mood symptoms of bipolar disorder: A systematic review and meta‐analysis
  46. Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses
  47. Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
  48. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
  49. Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder
  50. Clinical specificity profile for novel rapid acting antidepressant drugs
  51. Age or age of onset: which is the best criterion to classify late-life depression?
  52. Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
  53. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  54. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns
  55. Association between polygenic risk scores of subcortical brain volumes and antidepressant response: a meta-analysis
  56. Emotional side effects of antidepressants: a systematic review
  57. Epigenetic factors influencing the multimorbidity between somatic and brain-insulinopathies
  58. Pharmacological treatment of psychotic depression: a systematic review and network meta-analysis
  59. What emotional regulation strategies are most related to the affective symptoms of bipolar disorder? A systematic review and network meta-analysis
  60. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review
  61. LOCAL PATTERNS OF SHARED GENETICS AND A GENETIC LATENT FACTOR OF INSULIN RESISTANCE AND NEUROPSYCHIATRIC MULTIMORBIDITY
  62. PSYCHIATRIC AND INSULIN-RELATED SOMATIC MULTIMORBIDITY: INSIGHTS INTO UNDERLYING GENETIC ARCHITECTURE AND BRAIN STRUCTURES INVOLVED
  63. T75. NO LABELS NEEDED: UNDERSTANDING PSYCHIATRIC DISORDERS BASED ON GENETIC TRAITS
  64. Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study
  65. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  66. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs
  67. Temporally ordered associations between type 2 diabetes and brain disorders – a Danish register-based cohort study
  68. The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls
  69. Epigenetics and aetiology of mental illness
  70. Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
  71. The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
  72. Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder
  73. Depression, antidepressants, and insulin resistance: which link?
  74. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis
  75. Epigenetic Basis of Psychiatric Disorders: A Narrative Review
  76. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder
  77. Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
  78. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features
  79. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  80. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  81. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
  82. Bipolar disorder and comorbid substance use disorder: a machine-learning approach
  83. Genetic dissection of the clinical heterogeneity of major depressive disorder
  84. Hyperthyroidism and depression: a clinical case of atypical thyrotoxicosis manifestation
  85. Hyperthyroidism and depression: focusing on this complex interplay
  86. The Italian Version of the Brief Assessment of Cognition in Affective Disorders: Performance of Patients with Bipolar Disorder and Healthy Controls
  87. The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring – A systematic review and meta-analysis
  88. The cross-link between major depressive disorder and type 2 diabetes mellitus: a review of longitudinal and mendelian randomisation studies
  89. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts
  90. P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  91. W68. A META-ANALYSIS OF POLYGENIC RISK SCORES FOR MOOD DISORDERS, NEUROTICISM, AND SCHIZOPHRENIA IN ANTIDEPRESSANT RESPONSE
  92. TH59. INSULINOPATHIES OF THE BRAIN? GENETIC OVERLAP BETWEEN SOMATIC INSULIN-RELATED AND NEUROPSYCHIATRIC DISORDERS
  93. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis
  94. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response
  95. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  96. Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders
  97. Polygenic risk scores for psychiatric, inflammatory, and cardio-metabolic traits and diseases highlight possible genetic overlaps with suicide attempt and treatment-emergent suicidal ideation
  98. P.169 Genetic overlap between somatic insulin-related and neuro-psychiatric disorders
  99. P.171 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  100. P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt
  101. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder
  102. Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly
  103. P.306 Reduced chemokine ligand 1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  104. M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
  105. Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression
  106. P.4.01 C-X-C chemokine signalling is implicated in major depressive disorder in a sample of Korean elderly subjects
  107. SA92THE INFLUENCE OF THE SEROTONIN TRANSPORTER GENE 5-HTTLPR POLYMORPHISM ON SUICIDAL BEHAVIORS: A META-ANALYSIS
  108. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis
  109. The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis
  110. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans